The Supreme Court agreed Wednesday to review a major challenge to federal regulation of mifepristone, the medication used in a large share of U.S. abortions and in some miscarriage care. The Court will examine whether lower courts properly restricted changes the Food and Drug Administration made in 2016 and 2021 to the drug’s approved conditions of use, while an earlier Supreme Court stay leaves current access rules in place during the litigation.

The justices granted the government’s petition in FDA v. Alliance for Hippocratic Medicine and a related petition by manufacturer Danco Laboratories. The Court did not take the challengers’ separate cross-petition seeking review of the FDA’s original 2000 approval, narrowing the dispute now before the justices primarily to later regulatory actions.

The case focuses on how FDA changed access

FDA approved mifepristone in 2000 for medication abortion under specified restrictions. Over time, the agency revised those conditions based on accumulated evidence and its regulatory review. In 2016, FDA extended the approved gestational age from seven to ten weeks, reduced required in-person visits, broadened the categories of health professionals who could prescribe the drug and changed dosing and reporting requirements.

In 2021, during the COVID-19 public-health emergency, FDA said it would not enforce the in-person dispensing requirement under specified conditions. The agency later modified the Risk Evaluation and Mitigation Strategy to remove that requirement and permit certified pharmacies to dispense mifepristone. FDA’s current guidance explains the approved regimen through ten weeks of gestation and the certification requirements that remain in effect.

Anti-abortion medical organizations and physicians challenged those decisions in federal court in Texas. U.S. District Judge Matthew Kacsmaryk initially issued an order that would have suspended the drug’s approval nationwide. The Fifth Circuit later narrowed the relief, leaving the 2000 approval intact but concluding that the challengers could contest the 2016 and 2021 changes.

The Supreme Court’s April stay preserves the status quo

The litigation produced conflicting orders and rapid emergency appeals earlier this year. In April, the Supreme Court stayed the lower-court restrictions while appellate review proceeds. That means the Fifth Circuit’s limits have not taken effect, and mifepristone remains available under the federal rules in place before the litigation.

The federal government’s petition and briefs argue that the challengers lack Article III standing because they do not prescribe mifepristone and cannot show a sufficiently direct injury from FDA’s regulation of the drug. The government also argues that the lower courts improperly second-guessed the scientific and regulatory judgments of the agency charged by Congress with evaluating drug safety and effectiveness.

Associate Attorney General Vanita Gupta said in a Dec. 13 statement that the Justice Department welcomed Supreme Court review and would defend FDA’s actions. The administration warns that allowing courts to invalidate or rewrite drug-approval decisions based on contested scientific claims could create uncertainty extending beyond reproductive medicine.

Challengers argue FDA removed safeguards too aggressively

The Alliance for Hippocratic Medicine and individual physician plaintiffs argue that FDA did not adequately account for safety concerns when loosening the restrictions. Their position is that removing in-person dispensing and other conditions can increase the likelihood that emergency physicians will be asked to treat complications, creating professional and conscience-related injuries.

The central legal issue therefore includes standing before the merits can even be reached. The Supreme Court’s questions presented encompass whether the plaintiffs have standing and whether the Fifth Circuit properly evaluated FDA’s 2016 and 2021 actions under the Administrative Procedure Act.

Medical organizations supporting FDA say the drug’s safety record and the agency’s accumulated evidence justify the changes. The American College of Obstetricians and Gynecologists said in a Dec. 13 response that mifepristone has been used safely for more than two decades and urged the justices to prevent non-scientific challenges from disrupting evidence-based care.

The dispute is about both abortion and administrative authority

The practical consequences are substantial because medication abortion is now a central method of abortion in the United States, particularly after the Supreme Court’s 2022 decision in Dobbs v. Jackson Women’s Health Organization eliminated the federal constitutional right to abortion and returned broad regulatory authority to the states. Some states prohibit most abortions, while others protect access; federal drug rules intersect with that patchwork in complex ways.

The case also raises a broader administrative-law question: how much latitude courts should give FDA when experts at the agency revise conditions of use for an approved drug. FDA’s January 2023 approval letter reflects the agency’s formal implementation of the modified REMS, including certification requirements for prescribers and pharmacies.

If the challengers ultimately prevail on the 2016 and 2021 issues, access could revert to older conditions, potentially reducing the approved gestational period and restoring in-person dispensing constraints. If the government prevails, the current federal framework would remain intact, subject to state abortion laws and any future FDA actions.

A 2024 decision could reach far beyond one medication

Oral argument is expected next year, with a decision likely by the end of the Court’s term. Until then, the April stay governs, so Wednesday’s grant of review does not itself change how mifepristone may be prescribed or dispensed under federal law.

That continuity is important because the procedural history has generated public confusion. The Supreme Court has not ruled that FDA’s changes were lawful or unlawful; it has agreed to decide the questions after briefing and oral argument. Nor has it agreed in this case to revisit FDA’s original 2000 approval.

The stakes nevertheless extend beyond abortion policy. Drug manufacturers, physicians and regulators are watching whether courts can substantially alter an FDA-approved drug’s conditions of use based on a suit brought by parties who do not manufacture, prescribe or take the drug. The answer could influence how future challenges to agency scientific decisions are litigated.

For patients and clinicians, the near-term rule is simpler: the existing federal mifepristone framework remains operative while the Supreme Court prepares to hear the case. The major legal questions — standing, agency authority and the validity of the 2016 and 2021 changes — now move to the nation’s highest court for a definitive ruling.